Uncategorized
Ursapharm and Novaliq enter exclusive partnership, launch EvoTears
Novaliq and Ursapharm have entered an exclusive European partnership agreement and together have launched EvoTears, an over-the-counter treatment for evaporative dry eye disease.Under the agreement, Ursapharm obtains the exclusive license to commercialize Novaliq’s EvoTears, a multi-dose, non-aqueous, non-preserved lubricant eye drop, according to a press release from Novaliq.